VanEck Pharmaceutical ETF

NVO Gains Competitive Insight from New Study Approvals

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Novo Nordisk to Present New Analysis of Semaglutide ESSENCE Trial for MASH at 2026 EASL

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Novo Nordisk will host a Capital Markets Day on September 21, 2026

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Lexaria Gains Ethics Approval for Study Comparing its Semaglutide Formulation to Novo Nordisk's Wegovy

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Novo Nordisk to Hold Information Meeting

Investment firm Truffle explains its rationale for recently buying and selling Novo Nordisk stock

Sanofi Rare Disease Therapy Efdoralprin Alfa Shows Superiority Over Standard of Care in Trial Results

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Novo Nordisk provides an update on its share repurchase program

Novo Nordisk to hold R&D investor event at the American Diabetes Association (ADA) 2026 meeting

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Novo Nordisk Launches 15 Billion DKK Share Buyback Plan

Amesite

Meiwu Tech

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

MetaVia

Co-Diagnostics

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Novo Nordisk will present new analyses from its Phase 3 ESSENCE trial of semaglutide for MASH at the EASL Congress 2026. The trial shows favorable liver safety across patient subgroups, addressing concerns for clinicians. Subgroup analyses indicate benefits for a Japanese MASH cohort and menopausal women, supporting broader use. This update reinforces earlier results showing semaglutide's effectiveness in improving liver inflammation and scarring.

PUBT

Novo Nordisk AS

Novo Nordisk says ESSENCE trial shows semaglutide maintains favorable liver safety in MASH

The CDSCO has instructed states and UTs to monitor promotional activities for GLP-1 weight-loss drugs like semaglutide, following a ban on promotional activities for prescription-only therapies. The organization is enforcing compliance through audits and inspections, addressing illegal distribution and misuse. With the patent expiration of semaglutide, over 25 generic versions have emerged, prompting companies to launch multimedia campaigns focused on obesity awareness, as direct advertising is prohibited.

Business Standard

Eli Lilly

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

ELIL

ELIS

Trump purchased up to $680,000 in Eli Lilly stock amid favorable federal policies for its obesity drugs. Legal ethicists express concerns about the timing potentially undermining public trust, although Trump's team claims the trades are independently managed. This move reflects a broader shift from bonds to numerous stock trades linked to administration policies.

Direxion Daily LLY Bull 2X Shares

Direxion Daily LLY Bear 1X Shares

Trump purchased Eli Lilly stock as policies favored its drugs

HBM HOLDINGS-Bannounced preclinical data for LET003, a monoclonal antibody for obesity treatment developed using AI. The results indicate LET003 has superior pharmacokinetics compared to competitors and, when combined with semaglutide, enhances fat reduction while preserving lean mass. At lower doses, it matches the effects of higher-dose bimagrumab in promoting lean mass gain, suggesting its potential as a Best-in-Class obesity therapy.

AASTOCKS News

First Trust NYSE Arca Biotech Index Fd

HBM HOLDINGS-B

HBM HOLDINGS-B  Discloses Preclinical Data of AI Candidate Drug for Obesity Treatment

Merck has launched a Hypertension Risk Checker to raise awareness about elevated resting heart rates as a potential cardiovascular risk, coinciding with World Hypertension Day. The initiative aims to encourage proactive heart health management, addressing the fact that 1.4 billion people globally live with high blood pressure, many unaware of their condition. Merck emphasizes the importance of early detection and education in managing heart health, marking four decades of commitment to cardiovascular care in the Gulf region.

Zawya

Merck

Merck KGaA

ZAWYA: Merck marks World Hypertension Day with launch of Hypertension Risk Checker

ALPMY

4503

Astellas Pharma Inc. will present new oncology data at the 2026 ASCO Annual Meeting, highlighting long-term outcomes and clinical applications across various cancer types. Key presentations include a 3.5-year follow-up on enfortumab vedotin for urothelial carcinoma and updates on prostate cancer treatments. Additionally, Astellas will introduce findings on fezolinetant for managing vasomotor symptoms in breast cancer patients. These presentations underscore Astellas' commitment to enhancing cancer care.

- Astellas Pharma will present 10 abstracts, including two oral presentations, at the 2026 ASCO Annual Meeting, highlighting its commitment to oncology research.  
- Key topics include the effectiveness of enfortumab vedotin combined with pembrolizumab for urothelial carcinoma and updates on fezolinetant for managing symptoms in breast cancer patients.  
- These presentations aim to enhance clinical understanding and improve treatment decision-making for various cancer types.

StockTitan

Astellas Pharma

Astellas Pharma Inc.

Pfizer

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News

LLYX

Eli Lilly (LLY) has emerged as a leader in the obesity drug market with its GLP-1 based products, Mounjaro and Zepbound, significantly boosting its stock. However, concerns about policy uncertainties and elevated expectations suggest that the market may have already priced in much of the growth potential. While demand for obesity treatments remains strong, potential risks could lead to volatility, prompting a neutral stance on LLY.

Tip Ranks

Defiance Daily Target 2X Long LLY ETF

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Canada Post Corp Registered Pension Plan increased its stake in Pfizer Inc. (NYSE:PFE) by 13.8% in Q4, owning 390,128 shares valued at $9.71 million. Other institutional investors also raised their positions. Despite positive developments in Pfizer's pipeline, concerns about declining COVID sales and patent expirations persist, with the stock down 1.7%. Pfizer reported Q1 earnings of $0.75 per share, exceeding estimates, and set FY 2026 guidance at 2.800-3.000 EPS.

- Canada Post Corp Registered Pension Plan increased its holdings in Pfizer Inc. by 13.8%, owning 390,128 shares worth $9.7 million after purchasing an additional 47,286 shares in Q4.  
- Other institutional investors also increased their stakes, with Brighton Jones LLC growing its share by 1,282.4% to 666,318 shares valued at $17.7 million.  
- Despite a strong Q1 earnings report, Pfizer faces challenges related to declining COVID sales and patent expirations, impacting investor sentiment and stock performance.

Market Beat

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

VG Health

ALPS Medical Breakthrough

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

United Bankshares

SEI Investments

Pfizer Inc. $PFE Stock Holdings Boosted by Canada Post Corp Registered Pension Plan

Eli Lilly's stock rose 6.0% following positive late-phase obesity trial results for Zepbound and Foundayo, alongside a $4.5 billion investment in Indiana manufacturing. The data supports the company's strategy in obesity and metabolic drugs, crucial for future growth. However, reliance on a few incretin drugs poses risks amid competition and pricing pressures. Analysts project significant revenue growth, with some estimating a fair value of $1209, indicating a potential 20% upside from current prices.

Simplywall

Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?

Wall Street Zen upgraded Novo Nordisk A/S from a 'hold' to a 'buy' rating. This follows mixed ratings from other brokerages, with some downgrading the stock. Currently, Novo Nordisk has an average rating of 'Hold' and a consensus price target of $65.56. The stock opened at $44.71, with a market cap of $199.63 billion and a P/E ratio of 10.50. Recent earnings showed $1.03 EPS and $10.85 billion in revenue.

VanEck Pharmaceutical ETF(PPH.US)